Shots:

• Bayer to invest $5M in the three-year collaboration with an option to extend the collaboration- if agreed by both the companies. The companies will jointly develop a first-in-class oral small molecule-based NRT for the treatment of hemophilia A and B
• Bayer to get an option to license the product developed under the collaboration. The agreement will integrate CHOP's expertise in hemophilia and coagulation with Bayer's research capabilities
• The alliance has the potential to change the treatment paradigm for patients with hemophilia. Additionally- Bayer is currently working to develop gene therapy for hemophilia A patients which may reduce the frequency of treatment

Click here to­ read full press release/ article | Ref: Bayer | Image: Reuters